Table 1.
Characteristics of all identified studies.
| Author | Country | N | Age (median) |
Tumor grade (I.II/III.IV) |
Tumor size (<=cm/>, unclear) | Sampling site |
Tumor type |
Histological type |
Histological differentiation (G1/G2, G3, and unknown) |
Method | Attitude | Follow-up time (median) |
Survival outcome (OS, DFS) |
Cutoff | MicroRNA type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buffa FM, 2011 | UK | 219 | 55 | NR | 2.3 (median) | Tissue | Breast cancer | Ductal, lobular, mixed, and others | 129, 65, and 25 | qRT-PCR | Neg | 10 y | DFRS, RFS | Median | miR-128a, -342, -27b, -150 |
| Foekens JA, 2008 | The Netherlands | 298 | 52 | NR | 2 cm, 141/157 | Tissue | Breast cancer | ER+/LNN, triple-negative | 44, 161, and 93 | qRT-PCR | Pos | 99 m | MFS | Median | miR-7, -128a, and -516-3p |
| Gee et al., 2010 [19] | UK | 46 | 63 | 8, 38 | NR | Tissue | Head and neck cancers | HNSCC | 27, 19 | qRT-PCR | Pos | 41 m | OS, RFS | Median | miR-21, -10b |
| Greithe T1, 2009 | Germany | 56 | 61.7 | NR | NR | Tissue | Pancreatic cancer | PDAC | NR | qRT-PCR | Pos | 15.99 m | DSS | Median | miR-155, -203, -216, -217, and -222 |
| Greithe T2, 2011 | Germany | 78 | 57 | 44, 34 | NR | Tissue | Soft-tissue sarcoma | STS, LS, MFH, FS, RMS, LMS, NS, and Syn | 48, 30 | qRT-PCR | Pos | 66 m | DSS | Quartiles | |
| Rothe F, 2011 | USA | 73 | NR | NR | 2 cm, 43/29/1 | Tissue | Breast cancer | ER-positive, ER-negative | 35, 22, and 16 | qRT-PCR | Pos | 9.23 y | RFS | Median | miR-148a |
| 89 | NR | NR | 2 cm, 34/55 | Tissue | Breast cancer | ER-positive | 64, 17, and 8 | qRT-PCR | Pos | 7.12 y | RFS | Median | miR-149a | ||
| Toyama T, 2012 | Japan | 161 | NR | NR | 2 cm, 42/117/2 | Tissue |
Breast cancer | TNBC, ER-positive, HER2-negative | 86, 53, and 22 | qRT-PCR | Pos | 5.4 y | DFS, OS | Median | |
| Volinia S, 2012 | Italy, Columbia | 107 | NR | NR | NR | Tissue | Breast cancer | DCIS, IDC, metaplastic, atypical, medullary, apocrine, adenoid, normal | NR | qRT-PCR | Pos | NR | MFS, OS | Median | miR-127-3p, -185, -143, -let-7b, -21, -221, -652, -106b, -197, and -let-7i |
| Wotschofsky Z, 2012 | Germany | 89 | 65 | 55, 34 | 5 (median) | Tissue | Renal cell carcinoma | ccRCC nonmetastatic | 81, 8 | qRT-PCR | Neg | 33.8 m | RFS | Median | miR-122, -141, -155, -184, -200c, -224, and -514 |
| 22 | 62 | 3, 19 | 9 (median) | Tissue | Renal cell carcinoma | ccRCC metastatic | 8, 14 | qRT-PCR | Neg | 9.4 m | RFS | Median | miR-122, -141, -155, -184, -200c, -224, and -515 |
NR: not reference; qRT-PCR: quantitative reverse transcription-polymerase chain reaction; Pos: positive; Neg: negative; HNSCC: head and neck squamous cell carcinoma; PDAC: pancreatic ductal adenocarcinomas; STS: soft-tissue sarcoma; LS: liposarcoma; MFH: malignant fibrous histiocytoma; FS: fibrosarcoma; RMS: rhabdomyosarcoma; LMS: leiomyosarcoma; NS: neurogenic sarcoma; Syn: synovial sarcoma; TNBC: triple- negative breast cancers; ccRCC: clear cell renal cell carcinomas; G1, G2, and G3: histological different grades; DFRS: distant relapse-free survival; RFS: recurrence free survival; MFS: metastasis free survival; OS: overall survival; DSS: disease specific survival; DFS: disease free survival.